天然的黄酸皮诺布林显示出抗血栓活性,并抑制了败血性血栓形成
Gaoxiang Li1, Wenhua Liu1, Xingwen Da1
1Division of Cardiology, State Key Laboratory for Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
International immunopharmacology
|September 28, 2024
概括
皮诺森布林是一种天然化合物,有效地抑制了血小板激活和败血症诱导的血栓形成. 这种黄胺在治疗败血症方面表现有前途,通过减少炎症和改善动物模型中的生存率来治疗败血症.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
背景情况:
- 败血症是全球主要的死亡原因,其特点是宿主对感染的极端反应.
- 血小板是败血症病理生理学的关键参与者,有助于血栓形成和炎症,从而提高死亡率.
- 目前对败血症诱导的血栓的治疗方法有限,需要新的治疗策略.
研究的目的:
- 研究中的天然黄类物质pinocembrin,作为毒症的潜在治疗剂.
- 评估pinocembrin在减轻血小板激活和治疗与败血症相关的血栓的疗效.
- 阐明皮诺布林抗血小板和抗败血症作用背后的分子机制.
主要方法:
- 使用小鼠模型进行体内研究,以评估FeCl3诱导的动脉血栓症和原/上腺素诱导的肺血栓栓塞.
- 在体外实验中评估皮诺布林对血小板聚合,分泌和信号传递的影响.
- 涉及Src/Syk/PLCγ2/MAPK信号通路的机制研究.
- 使用结绑定和刺穿 (CLP) 和脂聚糖 (LPS) 诱导的小鼠模型进行败血症模拟.
主要成果:
- 皮诺坎布林在体内显著抑制了血栓形成,并在体内抑制了血小板激活,聚合和分泌.
- 该化合物通过抑制血小板中的Src/Syk/PLCγ2/MAPK信号通路而起作用.
- 在败血症模型 (CLP和LPS) 中,皮诺森布林减少了炎症性细胞因子释放和败血栓塞.
- 用皮诺布林治疗改善了败血症小鼠的生存率.
结论:
- 皮诺森布林表现出强大的抗血小板活性,使其成为治疗败血症诱导的血栓形成的有希望的候选人.
- 皮诺布林抑制血小板功能为败血症提供了一种新的治疗方法.
- 对皮诺布林的进一步研究可能会导致这种危及生命的疾病的新疗法.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
636
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
636
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
483
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
483
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
155
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
155
Venous Thrombosis III: Interprofessional Care
3
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
3
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
3
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
3
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
137
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
137


